Kinentia Biosciences was founded in 2007 to utilize its
platform chemoinformatics technology called Deep Data Mining
(DDM™) to aid our clients in the discovery and development of novel pharmaceutical
agents. DDM recognizes key risk
factors involved in the drug discovery process and has built in
process checks to mitigate this risk.
Our team of consultants has extensive experience in the areas of
global CRO and CMO management and materials
combining these capabilities with our platform technology Kinentia
can greatly facilitate and mitigate the risk associated with
pharmaceutical development. To
see how Kinentia can aid you in your drug discovery and
development efforts, please click
Contract Research and Manufacturing
In addition to consulting services Kinentia also offers contract
research and development activities to support your drug discovery
and development activities.
We cover the complete discovery and development spectrum
via in house preclinical support in the US and clinical support
via our network of manufacturing partners located both in the US
and Asia. For further
information on our CRO / CMO capabilities please click please
Through our subsidiary KCS, Kinentia
also offers an extensive catalog of chemical intermediates,
building blocks and natural products.
Many of these compounds are novel in nature and have been
selected due to their drug like properties.
For further information on KCS and to access the full
catalog please visit